Ethnopharmacology of human immunodeficiency virus in South Africa–a minireview by Bessong, PO & Obi, CL
African Journal of Biotechnology Vol. 5 (19), pp. 1693-1699, 2 October 2006 
Available online at http://www.academicjournals.org/AJB 








Ethnopharmacology of human immunodeficiency virus 
in South Africa–a minireview 
 
Pascal Obong Bessong* and Chikwelu Larry Obi 
 
Department of Microbiology, University of Venda, Thohoyandou, South Africa. 
 
Accepted 9 August, 2006 
 
Infection with the human immunodeficiency virus (HIV), the etiologic agent of acquired immune 
deficiency syndrome (AIDS), continues to pose an unprecedented public health problem of enormous 
proportions worldwide. Current treatment options for HIV/AIDS have not been satisfactory and the 
quest for effective curative or preventive therapies goes on. Plants are increasingly seen as an 
alternative source for the discovery of novel anti-HIV molecules. Africa, particularly southern Africa, 
endowed with a rich diversity of medicinal plants, represents the region of the world worse hit by HIV. 
Anecdotal evidence of the therapeutic benefits to AIDS patients of some plant-derived preparations 
abound. This mini-review takes a look at the evaluations of South African medicinal plants to determine 
their effects on HIV/AIDS, and the initial attempts at the isolation and characterization of putative anti-
HIV molecules.  
 





Human immunodeficiency virus (HIV) is currently the 
most significant infectious pathogen with devastating 
consequences. Since the description of HIV as the 
causative agent of acquired immune deficiency syndrome 
(AIDS), HIV has produced a worldwide pandemic. In 
2005, UNAIDS estimated that 40 million people were 
infected worldwide, with 25 million in sub-Saharan Africa, 
while approximately 2.4 million deaths were attributed to 
AIDS in 2005.  Southern Africa represents one of the 
subregions hardest hit by HIV. Base on antenatal 
seroprevalence surveys, infection levels surpass 30 
percent in Botswana, Lesotho, Malawi, South Africa and 
Swaziland; with Angola, Mozambique, Namibia, Zambia, 
and Zimbabwe having 5, 15, 18, 16 and 25 percent 
(UNAIDS, 2005). Recent data for South Africa suggests 
that prevalences are increasing in all age groups, and 
about 5 million people are infected with the virus. The 
high endemicity of HIV in Southern Africa is already 
taking its toll on the socio-economic aspects of societies 
(Rosen et al., 2004). National programmes for the 
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nately in the countries where they are most needed, due 
to the high costs of drug procurement, and limited human 
and structural resources. 
One characteristic feature of HIV is the high degree of 
variability of its genome among independent virus isola-
tes. This feature impacts many aspects of the biology of 
HIV, including tissue and target cell specificity, clinical 
spectrum and pathogenesis, geographic and temporal 
distribution of virus, susceptibility to antiretrovirals, and 
prospects of developing an effective cross-reactive vac-
cine. Secondly, infection with HIV sooner or later, creates 
a window for infections with other microbes, which were 
hitherto contained by the immune system, to become 
progressive. Added to this is the concern that weakened 
human immune systems may become favourable envi-
ronments for the adaptation of traditionally non-human 
infectious agents. Most importantly, there has been a 
fervent and continuous search for preventive and curative 
therapeutics in an effort to stem the spread of the 
pandemic (McMichael and Hanke, 2003; Pomerantz and 
Horn, 2003).  
The efficacies of clinically available HIV enzymes and 
fusion inhibitors have been limited by the selection and 
development of resistant variants, appreciable levels of 
toxicity  and the absence of a curative effect. As a cones- 




quence, the search for better anti-HIV agents continues. 
Alongside, the endeavours in designing HIV antagonists 
based on the structure, catalytic properties of its 
enzymes, and surface receptors, alternative approaches 
such as the search for secondary metabolites from plant 




PLANTS AS PROSPECTIVE SOURCES OF ANTI-HIV 
COMPOUNDS 
 
Several studies have demonstrated the inhibitory 
properties of a variety of crude plant extracts, as well as 
chemically characterized phytomolecules against differ-
rent stages of the life cycle of HIV. Some of these studies 
focused on plant parts used traditionally in specific 
geographic locales in the treatment of various forms of 
infectious diseases. Interestingly, a few plant derived 
compounds such as papavarine, glycyrrhizin and tricho-
santhin were seen to have promise and have been 
evaluated in AIDS patients. These developments show 
that useful anti-HIV agents could be obtained from plants 
sources (Vlietinck et al., 1998; De Clercq, 2000; Kong et 
al., 2003).  
Specific African-based studies have also indicated the 
potential of local medicinal plants for anti-HIV activity. 
Asres and colleagues (Asres et al., 2001) investigated 
the effect of 71 polar and nonpolar extracts from 21 
Ethiopian medicinal plants comprising 14 plant families 
on HIV-1 and HIV-2 replication. They found that the 
acetone fraction of the leaves of Combretum paniculatum 
(Vent.) and the methanol fraction of the leaves of 
Dodonaea angustifolia L.f. strongly inhibited HIV-1 
replication with selective indices of 6.4 and 4.9 
respectively. These extracts also prevented virus induced 
cytopathic effect by almost 100% using MT-4 cells as 
targets. The greatest degree of antiviral activity against 
HIV-2 was achieved with the acetone extract of C. 
paniculatum (EC50=: 3 g/ml), and a selective index of 32 
was noted for this extract. Polar extracts that were 
obtained by extraction with hydroalcohol, methanol or 
acetone exhibited inhibition of viral growth at subtoxic 
concentrations. In a Sudanese study, forty-eight metha-
nol and aqueous extracts from Sudanese plants were 
screened for their inhibitory activity on viral replication. 
Nineteen extracts showed inhibitory effects on HIV-
induced cytopathic effects (CPE) on MT-4 cells. Screen-
ing the extracts against HIV-1 protease (PR) by an HPLC 
assay, the methanol extracts of the bark and pods of 
Acacia nilotica, the leaves of Euphorbia granulata, and 
the stem-bark of Maytenus senegalensis, together with 
the aqueous extracts of the pods of A. nilotica and the 
stem-barks of M. senegalensis showed considerable 
inhibitory effects against HIV-1 PR (Hussein et al., 1999). 
Extract from the leaves of Combretum hartmannianum 
used in Sudan in the treatment of malaria and other tropi-





transcriptase (HIV-1 RT) at a concentration of 66 g/ml 
(Ali et al., 2002).  
Central Africa, particularly Cameroon, represents the 
region of the world with the greatest diversity of HIV 
variants. Indeed, all the genetic subtypes of HIV-1 major 
group M (subtypes A-D, F-H, J and K), the outliers (group 
O), and the non-M-non-O variants (group N), have been 
described in Cameroon. Coupled to these is the presence 
of circulating recombinant forms CRF01_AG, CRF02_AE, 
and CRF09_cpx (Simon et al., 1998; Zhong et al., 2003; 
Yamaguchi et al., 2004). Within a decade of the 
knowledge of the huge public health problem posed by 
HIV, the atropisomeric naphthylisoquinoline alkaloid 
dimers, michellamines A, B, and C, were isolated from 
Ancistrocladus korupensis from the Korup rainforest in 
the South West Province of Cameroon. Michellamine B 
was shown to inhibit HIV-induced cell killing and viral 
replication in a variety of human cell lines, and in cultures 
of human peripheral blood leukocytes and monocytes. 
Futhermore, Michellamine B was inhibitory to several 
laboratory and clinical strains of HIV-1, including the AZT-
resistant strain G910-6 and the pyridinone-resistant strain 
A17; as well as strains of HIV-2. However, the high 
toxicity of this compound to several human cell lines 
prevented its further evaluation (Boyd et al., 1994). Cos 
et al. (2002) in an in vitro investigation of a selection of 
Rwandan plants used in traditional medicine for the 
treatment of infections and/or rheumatoid diseases 
reported that an aqueous fraction from the leaves of 
Tithonia diversifolia had a strong anti-replicative property 
but with a high selective index of 461. El-Mekkawy and 
colleagues (1995), studying Egyptian plants used in 
folklore medicine for activity against HIV-1, through a 
bioassay-guided fractionation of the methanol extract of 
the fruit of Phylanthus emblica isolated Putranjivain A 
with a potent inhibitory effect on HIV-1 RT (IC50 = 3.9 
M). The mode of action of Putranjivain A was seen to be 
non-competitive with respect to the substrate, but 
competitive with respect to the template-primer.  
 
 
SOUTH AFRICAN MEDICINAL PLANTS INHIBITORY 
TO HIV 
 
Laboratory based investigations of South African 
medicinal plants against HIV have sought to seek 
inhibitory properties of water and organic extracts, and 
isolated compounds against the essential enzymes RT, 
integrase (IN) and PR. RT converts the viral RNA 
genome to viral DNA using its polymerase domain (RNA-
dependent DNA polymerase activity), while the 
ribonuclease H (RNase H) domain degrades the RNA 
component from the intermediary RNA/DNA complex. 
The enzyme also has a DNA-dependent DNA polymer-
rase function. Integrase in conjunction with accessory 
viral proteins, namely the matrix and viral protein U and 
nuclear import signals is required for the transportation of 





and catalyzes its integration into the chromosome of the 
host cell. Protease cleaves viral polyproteins into 
structural and functional components which are 
assembled to form progeny virions. The selection of 
plants for anti-HIV evaluation has been mainly done 
through an ethnobotanical survey, in which plants whose 
decoctions have been reported by traditional healers to 
be of therapeutic value are selected for antiviral 
evaluation. 
 In one of our in vitro studies to directly assess the 
inhibitory effects of South African medicinal plants on 
HIV, using a radioactive cell free assay a strong inhibition 
(IC50 = 7.5 g/ml) by the methanol extract of the leaves of 
Terminalia sericea (Combretaceae) against the ability of 
RT to form a complementary DNA strand was observed 
(Bessong et al., 2004). This extract also inhibited the 
RNase H activity by a similar magnitude (IC50 = 8.1 
g/ml). Harnett et al. (2005) described a significant 
reduction in the activity of HIV RT by the water extracts of 
the leaves of Lebostomon trigonus (Boraginaceae) with a 
50% inhibitory concentration (IC50) of 49.0 g/ml. A 
minimal inhibition was also noted for Sutherlandia 
frutescens L. Br. (Fabaceae). No activity against HIV-2 
protease was observed. In our own studies, following a 
bioassay guided fractionation, we determined that a 
partially characterized red coloured gallotannin isolated 
from an active fraction of the methanol extract of the 
stem-bark and roots of Peltophorum africanum Sond. 
(Fabaceae), strongly inhibited RT functions, and the 3’-
end processing activity of IN (Bessong et al., 2005). 
Specific and non-specific binding of polyphenols to 
receptors have been described (Wall et al., 1996; Zhu et 
al., 1997), so whether the activity of this gallotannin is 
non-specific or of broad spectrum remains to be 
determined. We also showed that catechin equally 
derived from the stem-bark of P. africanum inhibited the 
3’-end processing activity of HIV-1 IN by as much as 65% 
at 100 M, but had no activity on HIV-1 RT. Details of 
methodologies and outcomes of studies in which South 
African plants have been investigated for anti-HIV 
replicative properties are presented in Table 1.  
 
 
SUGGESTIONS FOR EXPERIMENTAL APPROACHES  
 
HIV-1 RT uses magnesium or manganese divalent ions 
as a co-factor, but activity is optimal with magnesium 
ions. A marginal increase in the concentration of 
manganese ions retards HIV-1 RT activity (Bolton et al., 
2002). Furthermore, Filler and coworkers (Filler and 
Lever, 1997) have showed the irreversible inhibition of 
RT by palladium and iron, and the subsequent reduction 
in virus proliferation. Ions of manganese, palladium and 
iron may be found in soils and subsequently in plant sap. 
Most methodologies describing the inhibition of HIV RT 
by crude plant extracts do not take into consideration the 
effect of metal ions in regulating the  activity  of HIV-1 RT.  




Consequently, it would be important to determine metal 
ions in plant extracts prior to screening in order to avoid 
false inhibitory observations at the screening stage. 
 Most clinically available RT drugs target the polymer-
rase function of the enzyme. However, it has been shown 
that point mutations in the RNase H domain of RT 
significantly reduce viral proliferation (Tarrago-Litvak et 
al., 2002). Hence, it would be interesting to seek plant-
derived molecules which have activity against either the 
RNase H or the polymerase domain. Although a few 
drugs minimally interact with the RNase H function, the 
identification of an extract against the RNase H but not 
the polymerase domain or vice versa may signify a 
unique molecule of significant specificity. In addition, 
despite the high toxicity ascribed to some identified anti 
integrase molecules, this enzyme should remain an 
interesting target to arrest retroviral replication, since no 
cellular homologue exists. Investigations on the biological 
activity of plant extracts against the strand transfer, 3’-
end processing and concerted integration functions of IN, 
crucial steps in the establishment of infection and viable 
therapeutic targets, would widen the scope of the search 
for plant-based anti-HIV molecules.   
 
 
SOUTH AFRICAN PLANTS AND AIDS 
 
South Africa, one of the countries with a huge HIV/AIDS 
crisis, has a rich diversity of medicinal plants and 
members of different indigenous communities have 
tapped the medical benefits of plants for centuries. 
Evidently, a good proportion of South African HIV/AIDS 
patients, for traditional and financial reasons, seek 
treatment from traditional healers who administer 
different preparations from a variety of plants. In some 
quarters, the usefulness of these preparations receives 
applause, while to others its remains an open question 
and sometimes controversial.  
One of the earliest investigations on a South African 
plant deemed to be useful to HIV/AIDS patients was the 
cytotoxicity tests on Sutherlandia frutescens subspecies 
microphylla (Fabaceae). This plant is widely used for its 
reported ability to increase CD4 counts and decrease 
viral load in AIDS patients (www.sutherlandia.org/aids). 
The in vivo studies carried in 2000 by the Indigenous 
Knowledge Systems Unit of the South African Medical 
Research Council (MRC) in velvet monkeys noted that 
when the monkeys were fed with powdered leaves of S. 
frutescens for a period of three months there were no 
nefarious outcomes when a battery of hematological, 
physiological and biochemical parameters were analy-
zed. Although the use of a particular plant for decades 
may point to its pharmacological safety, the MRC results 
were very significant and encouraging considering the 
large number of people who take S. frutescens for relief.  
In a study to clinically assess the efficacy of South 
African traditional medicine on viral load and CD4 counts,




Table 1. South African medicinal plants studied for anti-HIV properties; assays used and main findings.  
 
Plants investigated Type of 
extracts/compounds 
investigated 
Test system used 
and viral target 
Significant outcomes Reference 
Terminalia sericea Burch. Ex Dc 
(Combretaceae), Combretum molle R. Br. Ex 
G. Don (Combretaceae), Bridelia micrantha 
Baill.(Euphorbiaceae). 
Water and methanol 




1RT expressed in 
Saccharomyces 
cerevisiae. Inhibition of 
polymerase and 
RNase H functions of 
RT were studied. 
Methanol extract of T. sericea inhibited the 
polymerase and RNase functions with IC50 of 
7.2 and 8.1 g/ml respectively. 
Bessong et al., 
2004 
Lobostemon trigonus (Boraginacea), 
Sutherlandia frutescens L. Ex Br.  (Fabaceae),  
Water, methanol, 
acetone, ethanol and 
methylene dichloride 
extracts of the leaves 
and flowers of S. 





transfer assays. RT 
and PR activities were 
investigated. 
Aqueous extract of L. trigonus inhibited HIV-1 
RT with an IC50 of 49 g/ml. 
Harnett et al., 
2005  
Peltophorum africanum Sond. (Fabaceae), 
Sutherlandia frutescens subspecies micropylla 
L.. R.Br.ex W.T. Aiton (Fabaceae), Vernonia 
stipulacea Klatt. (Asteraceae), Ziziphus 
mucronata Willd. (Rhamnaceae), Ricinus 
communis L. (Euphorbiaceae), Elaendendron 
tranvaalensis Jacq. (Celasteraceae), Mucuna 
coriacea Baker (Fabaceae), Bridelia micrantha 
Baill. (Euphorbiaceae), Combretum molle 
R.Br.ex G. Don (Combretaceae) 
Water and methanol 
extracts of roots, leaves 
and stem-barks. A 
partially characterized 
gallotannin; bergenin 
and catechin  isolated 




1RT and IN expressed 
in Saccharomyces 
cerevisiae. Inhibition of 
polymerase and 
RNase H functions of 
RT, and 3’-end 
processing activity of 
IN was studied.  
Methanol extract of the stem-bark of P. 
africanum inhibited the polymerase and RNase 
H functions of RT with IC50 of 3.5 g/ml and 
5.0 g/ml respectively. The gallotannin 
inhibited the polymerase and RNase activities 
with IC50 of 6.0 M and 5.0 M respectively, 
and abolished the 3’-end processing activity of 
IN at 100 M. Catechin reduced IN activity by 
65% at 100 M.  The aqueous and methanol 
extracts were non-toxic to a HeLaP4 cell line 
at a concentration of 400 g/ml. 
Bessong et al., 
2005   
Sutherlandia frutescens subspecies micropylla 
L.. R.Br.ex W.T. Aiton (Fabaceae), Vernonia 
stipulacea Klatt. (Asteraceae), Ricinus 
communis L. (Euphorbiaceae), Elaendendron 
tranvaalensis Jacq. (Celasteraceae), Mucuna 
coriacea Baker (Fabaceae), Bridelia micrantha 
Baill. (Euphorbiaceae). 
Butanol and acetyl 
acetate fractions of the 
methanol extracts of 
roots. ß-sistosterol and 
friedelin isolated from 
the roots of B. 
micrantha 
Radioactive cell free 
systems employing 
recombinant HIV-1 RT 
and HIV-1 IN 
ß-sistosterol and friedelin had no effect on 
HIV-1 RT and 3’-processong activity of HIV-1 
IN. The ethyl acetate fraction of the roots of B. 
micrantha showed an IC50 of  7.3 g/ml on 
RDDP activity of  RT, but had no effect on 3’-
processing activity of HIV-1 IN 











Tshibangu et al. (2004) described an improvement in the 
immune system and general well-being of patients, due 
to increases in CD4+ T cell and decrease in viral load, 
when these markers were monitored for 12 months in 
HIV/AIDS participants.  
AIDS is a syndrome comprising a dysfunction of the 
immune system, compounded by opportunistic infections 
of bacterial, fungal, protozoan or viral aetiology. The 
beneficial effect of a plant-derived extract administered to 
HIV/AIDS patients could be due to one or a combination 
of several factors: a direct inhibition of HIV replication, 
boosting of the immune system, or having inhibitory 
properties against one or several opportunistic infections. 
The stories of ‘successful’ herbal therapy against 
HIV/AIDS have components of cures relating to skin, 
respiratory, intestinal disease manifestations, and re-
establishment of vitality. These are pathologies closely 
tied to fungal, bacterial and other viral infections. Many 
investigations have documented the biological activity of 
South African plants against bacteria, fungi, viruses, 
protozoans and non-infectious conditions. In these 
studies, the use of plants in traditional medicine was 
validated by the demonstration of antimicrobial action of 
crude plant extracts against potential pathogens, and in 
some cases molecules with specific bioactivity were 
identified (Meyer et al., 1997; Fennel et al., 2004; 
Tshikalange et al., 2005). Of interest are those organisms 
which are common opportunistic infections in AIDS-
related complex and AIDS. Diospyrin isolated from 
Euclea natalensis (Ebenaceae) and its amino acetate 
derivative is active against sensitive and resistant strains 
of Mycobacterium tuberculosis, the cause of tuberculosis, 
and a case defining illness in AIDS (Lall and Meyer, 
2001; Lall et al., 2003). In our own studies (Obi et al., 
2002; Obi et al., 2003), we reported the antibacterial 
activity of aqueous and methanol extracts of Venda 
medicinal plants against enteropathogens such as 
Campylobacter responsible for Campylobacter-associa-
ted diarrhea in HIV/AIDS patients with substantial 
morbidity and mortality (Quinn, 1997; Coker et al., 2002). 
Motsie and colleagues (2003) reported the antifungal 
effect of extracts from Polygala myrtifolia (Polygalaceae) 
and Glycyrrhiza glabra (Fabaceae) against Candida 
albicans, responsible in the most part for oral and 
oesophagal thrush common in AIDS patients (Lattif et al., 
2004). Methanol and aqueous extracts of Dombeya 
rotondifolia (Hochst.), Terminalia sericea and Gunnera 
perpensa are bactericidal against Staphylococcus 
aureus, implicated in skin infections (Miller et al., 2003), 
and that this activity is mediated by fatty acids in the 
extracts (Reid et al., 2005). In addition, many plant 
species are rich in sterols and sterolines which have 
been shown to have immuno-modulatory effects and 
boost the vitality of AIDS patients (Bouic et al., 2001; 
Bouic, 2002). An on-going bioassay-guided fractionation 
of the roots of Bridelia micrantha Baill. (Euphorbaceae), 
ethnobotanically selected to study its effects on HIV  enz- 




ymes, has yielded the phytosterols -sistosterol and 
fredelin (Bessong et al., 2006). Whether -sistosterol and 
fredelin contribute to the well-being of patients and as 
such give the plant a spot in the HIV/AIDS pharmaco-
poeia of some Venda traditional healers remains to be 
determined.  
There is therefore good reason to expect an 
appreciable clinical management of an AIDS patient 
presenting with a fungal infection such as candiadiasis, 
diarrhea of bacterial etiology and fever, and treated with 
plant extracts known to kill fungi, reduce stool output and 
are antipyretic.  Even though, the extracts have no direct 
virucidal effect, minimizing the opportunistic infections 
improves the well-being of the individual. However, for 
purposes of empiric evidence, and as a means of 
identifying specific anti-HIV/AIDS properties of different 
plants preparations, the performance of concomitant 
investigations of the antibacterial, antifungal and 
immunostimulatory effects when plants are evaluated for 
anti-HIV properties will provide a vast array of valuable 
data from which the antimicrobial properties of a 






Once AIDS was defined and HIV identified as the 
underlying cause, the determination of its modes of 
transmission and development of effective diagnostics 
were relatively rapid. Even the first antiretroviral for HIV 
(zidovudine) was already ‘at hand’. These early 
successes highlight the perennial importance of basic 
research in the generation of a pool of knowledge and 
information easily harnessed to answer new questions.   
Due to the rampant administration of plant-based 
decoctions and concoction to HIV/AIDS individuals and 
the numerous anecdotes of the benefits derived from 
plant-based preparations, research on the anti-HIV 
replicative properties of South African medicinal plants is 
on the increase. Huge financial and human capital are 
required to pursue the search of novel anti-HIV molecules 
through systematic screening, isolating, identifying active 
ingredients, verifying their mode of action, specificity, 
toxicity evaluations and interactions with antiretrovirals. 
The deteriorating AIDS situation in South Africa and 
Southern Africa as a whole calls for such a commitment. 
It is only through these investments that outcomes of high 
value to the efforts geared at identifying molecules that 
could serve as templates in obtaining better anti-HIV 
molecules would be achieved. In addition, concrete 
answers are required from the scientific community on 
what specific benefits could be derived from the use of 
medicinal plants by HIV/AIDS patients. 
The HIV situation in North America and Europe is 
stabilizing and decreasing in some populations. It is 
plausible that in several years to come HIV will no longer  




be a concern for nations of these parts of the world. The 
implication is that research efforts in the development of 
therapeutics will dwindle, reminiscent of the tuberculosis 
and malaria situations. The World Health organization 
estimates that about 80% of the population of developing 
countries makes use of plant based traditional medicine 
for their primary health care needs. Coupled with the 
challenge of widespread antimicrobial resistance, herbal 
medicine and traditional healers are receiving more 
attention. Invigorating medicinal plant research on HIV 
with defined goals has broad expected outcomes in terms 
of human capacity and biotechnology development, and 
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